Citrobacter koseri is a rod-shaped bacterium that lives harmlessly in the gut of many healthy people but can cause serious, sometimes life-threatening infections when it reaches parts of the body where it does not belong. It belongs to the same broad family as better-known gut bacteria like E. coli and Klebsiella, and it shares their knack for thriving in hospital environments and acquiring resistance to antibiotics. What sets C. koseri apart is a disturbing tendency to cause brain abscesses in newborns, a complication rare among other members of its family and one that drives much of the clinical concern around this organism.
What C. Koseri Is and Where It Lives
C. koseri is a Gram-negative bacterium, meaning it has a double-layered outer membrane that makes it naturally resistant to certain antibiotics. It is part of the Enterobacteriaceae family, a large group of bacteria commonly found in the human digestive tract.1Frontiers in Antibiotics. A brief insight into Citrobacter species – a growing threat to public health One of its defining features is its ability to use citrate as its sole carbon source, which is actually how the genus Citrobacter got its name.2PubMed Central. Severe asthma patient with secondary Citrobacter koseri abdominal infection: first case report and review of the literature
Outside the human body, C. koseri turns up in soil, water, sewage, and food. Inside the body, it colonizes the gastrointestinal and genitourinary tracts of both humans and animals without causing any symptoms in the vast majority of carriers.3Journal of Microbiology & Experimentation. Antimicrobial susceptibility of Citrobacter koseri isolated on clinical samples of hospitalized patients This dual existence as both a harmless gut resident and a potential pathogen is what makes C. koseri an opportunistic organism: it waits for circumstances, like a weakened immune system or a break in the body’s normal barriers, before causing trouble.
Who Is at Risk
C. koseri rarely causes disease in healthy adults with intact immune systems.4PubMed Central. Infective endocarditis due to Citrobacter koseri in an immunocompetent adult When it does cause infection, the people it hits hardest tend to fall into a few groups. Newborns, especially premature infants, are the most vulnerable population. The elderly and people with chronic conditions like diabetes, cancer, or hypertension also face elevated risk, as do patients whose immune systems are suppressed by medications or disease.5PubMed Central. Osteomyelitis Caused by Citrobacter koseri in a Young Immunocompetent Man
In immunocompromised adults, the most common infection sites are the urinary tract, the gastrointestinal system, and the respiratory tract. In newborns, the picture shifts: the bloodstream and the membranes surrounding the brain are the primary targets.5PubMed Central. Osteomyelitis Caused by Citrobacter koseri in a Young Immunocompetent Man That difference in clinical presentation between adults and newborns is one of the most important things to understand about this organism.
How C. Koseri Spreads
Transmission can happen through several routes, and the setting matters enormously. In hospitals, C. koseri spreads from contaminated surfaces, equipment, and even the hands of healthcare workers to vulnerable patients. One investigation traced a neonatal meningitis case to bathroom sinks that were being used to rinse infant bottles. Molecular testing confirmed that the strain found in the sink matched the one infecting the baby.6Pediatrics. Hospital-Acquired Citrobacter Meningitis Complicated by Pneumocephalus in a Neonate This kind of environmental reservoir is a recurring theme in hospital outbreaks involving Gram-negative bacteria: wet surfaces like sinks, drains, and tubing provide ideal conditions for these organisms to persist.
Vertical transmission from mother to infant is another documented route. In one case, a pregnant woman with an infection of the amniotic membranes and bloodstream infection passed C. koseri to her baby, who was born in septic shock. Molecular fingerprinting confirmed the maternal and infant strains were identical, ruling out a separate hospital source.7PubMed. Transmission of Citrobacter koseri from mother to infant documented by ribotyping and pulsed-field gel electrophoresis Although vertical transmission is considered rare, additional cases have been documented where both mother and infant developed overwhelming sepsis from the same Citrobacter species.8PubMed. Vertical transmission of a Citrobacter infection
For healthy adults outside the hospital, C. koseri poses very little transmission risk. It is not a contagious pathogen in the way you might worry about the flu or a stomach virus. The infections it causes are almost always tied to healthcare settings, underlying illness, or the vulnerability of very young immune systems.
Why Brain Abscesses in Newborns
The feature that distinguishes C. koseri from most other Enterobacteriaceae is its strong association with brain abscesses in neonates. This is not merely a matter of the immature immune system being too weak to fight off infection, though that plays a role. The bacterium itself has a specific biological trick: it can survive and multiply inside macrophages, the very immune cells that are supposed to kill it.
Research using neonatal rat models showed that macrophages, not other brain cell types like neurons or astrocytes, were the primary host cells for long-term C. koseri infection. More than 90% of the bacteria inside these immune cells were found within compartments called phagolysosomes, structures that normally destroy engulfed microbes with enzymes and acid. C. koseri survives this killing machinery.9PubMed Central. Citrobacter koseri brain abscess in the neonatal rat: survival and replication within human and rat macrophages In effect, the bacterium hijacks the immune cell meant to destroy it, turning it into a safe house for replication.
The consequences of this are severe. As infected macrophages and neutrophils accumulate in the brain, the surrounding tissue dies, and the pocket of dead tissue and immune cells expands into an abscess.10PubMed Central. Favorable outcome in cerebral abscesses caused by Citrobacter koseri in a newborn infant These abscesses tend to be multiple and can grow rapidly, which is why C. koseri meningitis in neonates carries a high mortality rate and leaves many survivors with lasting neurological damage.11PubMed Central. Neonatal Citrobacter koseri Meningitis: Report of Four Cases
Infections in Adults
Although the neonatal brain abscess story dominates the literature, C. koseri does cause a range of infections in adults. Urinary tract infections are the most common, particularly in hospitalized patients with catheters. Respiratory infections, wound infections, and bloodstream infections also occur, generally in people with weakened immune defenses or chronic illness.
Rarer presentations have been documented in case reports. One case involved infective endocarditis, an infection of the heart valves, in an otherwise healthy adult, which caught clinicians off guard because C. koseri is so strongly typed as an opportunistic pathogen.4PubMed Central. Infective endocarditis due to Citrobacter koseri in an immunocompetent adult Another case report described osteomyelitis, a bone infection, in a young man with no immune compromise.5PubMed Central. Osteomyelitis Caused by Citrobacter koseri in a Young Immunocompetent Man Brain abscesses, while far more characteristic of neonates, have also been documented in adults. One adult case involved a large abscess in the frontal lobe of the brain, confirmed by pus culture.12PubMed Central. Brain abscess caused by Citrobacter koseri infection in an adult These cases are uncommon enough to warrant individual case reports, which tells you how unusual they are, but they serve as reminders that the organism can occasionally punch above its weight.
Diagnosis
Identifying C. koseri starts with standard microbiological culture. When a clinician suspects infection, samples of blood, urine, cerebrospinal fluid, or pus are sent to the lab, where the bacteria are grown on culture media and identified by their biochemical characteristics. Modern labs increasingly use a technique called MALDI-TOF mass spectrometry, which identifies bacteria by their protein fingerprint within minutes rather than the hours or days that conventional biochemical testing requires.13American Journal of Clinical Pathology. Microarray-Based Nucleic Acid Assay and MALDI-TOF MS Analysis for the Detection of Gram-Negative Bacteria in Direct Blood Cultures One caveat with automated systems is that closely related species within Citrobacter can occasionally be misidentified, so clinicians sometimes rely on molecular confirmation when the stakes are high.
When brain involvement is suspected, especially in neonates, imaging is critical. MRI is the preferred tool because it provides detailed views of abscess formation. Bacterial brain abscesses show a characteristic pattern on MRI: a capsule that lights up brightly on certain sequences, and restricted water diffusion inside the abscess cavity that creates a distinct bright signal on diffusion-weighted imaging.14PubMed Central. Multiple Brain Abscesses Caused by Citrobacter Koseri in a Preterm Neonate – Case Report These imaging features help distinguish abscesses from tumors or other brain lesions and guide decisions about whether surgical drainage is needed.
Antibiotic Resistance
Like many Gram-negative bacteria, C. koseri carries built-in resistance to some antibiotics. Every C. koseri genome examined in one large genomic study contained a gene called blaCKO, which encodes an enzyme that breaks down certain penicillins and early-generation cephalosporins. This resistance is chromosomal, meaning it is an inherent part of the organism’s DNA rather than something acquired from other bacteria.15PubMed Central. Genomic analysis of antibiotic resistance and virulence factors in the uropathogen Citrobacter koseri In practical terms, this means that simple penicillins and first-generation cephalosporins are generally not effective against C. koseri, and treatment needs to start with drugs that can overcome this baseline resistance.
The more alarming trend is the acquisition of additional resistance mechanisms on top of this innate resistance. A study of Citrobacter isolates from Japan found that about a third of C. koseri strains produced extended-spectrum beta-lactamases (ESBLs), enzymes that break down a much wider range of antibiotics, including newer cephalosporins. In some regions of southern Japan, the ESBL rate reached 60%.16PubMed. High prevalence of extended-spectrum β-lactamases and qnr determinants in Citrobacter species from Japan: dissemination of CTX-M-2 The emergence and spread of resistance to carbapenems, fluoroquinolones, aminoglycosides, and even colistin, a last-resort drug, across Citrobacter species has been documented and is considered a growing public health threat.1Frontiers in Antibiotics. A brief insight into Citrobacter species – a growing threat to public health
This resistance landscape means that antibiotic selection cannot be done on autopilot. Susceptibility testing, where the lab checks which drugs the particular strain responds to, is essential for guiding treatment.
Treatment
Treatment for C. koseri infection always hinges on susceptibility testing, but clinicians often need to start antibiotics before those results come back. The classes of antibiotics commonly used include aminoglycosides, carbapenems, cephalosporins, chloramphenicol, and fluoroquinolones.17PubMed. Optimum management of Citrobacter koseri infection For straightforward urinary tract or soft tissue infections in adults, a fluoroquinolone or a later-generation cephalosporin often suffices, assuming the strain is susceptible.
The real treatment challenges arise with invasive neonatal infections, particularly meningitis and brain abscesses. For these cases, carbapenems like meropenem are considered a cornerstone of therapy. One treatment approach that has shown promise combines a carbapenem with cefotaxime, a third-generation cephalosporin, sometimes alongside ciprofloxacin.18PubMed. Treatment of Citrobacter koseri infection with ciprofloxacin and cefotaxime in a preterm infant The rationale for combination therapy is partly about achieving adequate drug levels in the brain, which is separated from the bloodstream by a selective barrier that many antibiotics cannot easily cross, and partly about preventing resistance from emerging during a prolonged treatment course.
When brain abscesses form, antibiotics alone are often not enough. Surgical drainage of the abscess may be necessary, and the combination of carbapenems with surgical intervention has been described as playing an important role in outcomes.19PubMed. Long-Term outcome of neonatal Citrobacter koseri (diversus) meningitis treated with imipenem/meropenem and surgical drainage Even with aggressive therapy, the prognosis for neonatal C. koseri meningitis with brain abscesses remains guarded. Case series consistently describe high mortality and serious long-term neurological problems in survivors, including developmental delays, seizure disorders, and motor impairments, even when treatment was started early and appeared adequate.11PubMed Central. Neonatal Citrobacter koseri Meningitis: Report of Four Cases
Preventing Hospital Outbreaks
Because the most devastating C. koseri infections occur in neonatal units, prevention efforts focus heavily on these settings. The hospital outbreak traced to contaminated bathroom sinks illustrates both the difficulty and the necessity of environmental surveillance. After the initial case was identified, the hospital implemented a multi-layered response: isolating colonized neonates, reinforcing hand hygiene among healthcare staff, screening neonates with regular cultures, and decontaminating surfaces with chlorine solutions. Despite these measures, four additional cases occurred over the following year and a half.6Pediatrics. Hospital-Acquired Citrobacter Meningitis Complicated by Pneumocephalus in a Neonate
The persistence of the outbreak led to more aggressive interventions. Neonates were physically separated into dedicated rooms based on their colonization status using a color-coded system: red rooms for babies with positive cultures, yellow for those with pending results, and green for negative results. Screening was intensified to include rectal and throat swabs at birth and every 48 hours thereafter. Staff were screened via swabs of their hands, throats, and skin folds. Formula milk, air, and water were all sampled. Only after this comprehensive approach was fully implemented did the outbreak stop.6Pediatrics. Hospital-Acquired Citrobacter Meningitis Complicated by Pneumocephalus in a Neonate
The lesson from that experience is sobering: standard infection-control measures were not enough to stop transmission. It took an almost forensic level of environmental investigation and physical separation of patients to bring the outbreak under control. For neonatal units, this underscores why C. koseri is treated with particular seriousness even though it is a relatively uncommon cause of infection overall.
The Naming History
If you encounter older medical literature, you may see C. koseri referred to as Citrobacter diversus. The two names refer to the same organism. The reclassification happened as molecular techniques replaced older biochemical methods for defining bacterial species. The name C. diversus still appears in papers from the 1980s and 1990s and in some older textbook editions, so knowing the equivalence is useful when reading case reports from that era. The broader genus Citrobacter now includes 19 recognized species based on genomic analysis, with C. freundii and C. koseri being the two most clinically significant.1Frontiers in Antibiotics. A brief insight into Citrobacter species – a growing threat to public health C. freundii is more commonly isolated overall, but C. koseri commands outsized attention because of its neonatal brain abscess association and its higher rates of ESBL production compared to C. freundii.16PubMed. High prevalence of extended-spectrum β-lactamases and qnr determinants in Citrobacter species from Japan: dissemination of CTX-M-2
How C. Koseri Compares to Other Gram-Negative Opportunists
In the larger landscape of hospital-acquired Gram-negative infections, C. koseri occupies a niche. It is far less common than organisms like Pseudomonas, Klebsiella, or Acinetobacter in intensive care units, and it does not generate the same level of public health alarm as carbapenem-resistant Enterobacteriaceae. But its propensity for central nervous system infection in neonates, combined with the intracellular survival mechanism described above, makes it uniquely dangerous in that specific context. A pediatrician or neonatologist hearing “Citrobacter koseri” in a blood culture result will take it very differently from a urologist seeing it in an adult urine sample.
For adult patients, C. koseri infections typically respond well to appropriate antibiotics and carry a prognosis similar to other Gram-negative urinary or respiratory infections. The key variable is whether the strain is resistant to the drugs being used. As ESBL-producing strains become more common, empiric treatment choices may need to shift toward carbapenems more often, which places additional pressure on a drug class that clinicians are trying to preserve as a last resort. That tension between treating the individual patient and protecting the broader population from carbapenem resistance is not unique to Citrobacter, but it applies here as it does across all Enterobacteriaceae infections.